The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.
The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.
The user is using oral minoxidil and dutasteride for hair loss and observed changes in blood pressure after taking oral minoxidil. They experienced no visible symptoms from topical minoxidil, finasteride, or other treatments and are seeking feedback on whether these blood pressure changes are typical for oral minoxidil users.
Some people don't see results with FDA-approved hair loss treatments like finasteride or minoxidil due to underlying issues. The video suggests addressing these issues, especially if there are atypical symptoms or other health conditions.
The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.
The user experienced side effects from oral finasteride and is considering microdosing topical finasteride mixed with minoxidil. They plan to mix Hims min/fin with Kirkland minoxidil to achieve a lower dose of topical finasteride.
Topical RU58841 is discussed for hair loss treatment, with a focus on brands available in Europe that have low systemic absorption. Users suggest mixing your own solution to control vehicle and dosage, and mention different brands like Actifolic and Biolabshop.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
Intermittent finasteride dosing, like taking it every third day, may reduce side effects while still lowering DHT levels. Users report side effects such as brain fog and weaker erections, which often subside after stopping the drug.
The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.
RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
The user completed their first month using oral finasteride and topical minoxidil without issues but is concerned about a 2-3 day gap in their finasteride supply affecting progress. They are also seeking advice on obtaining a multi-month supply.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The user is experiencing hair shedding despite using finasteride, minoxidil, and microneedling, and is concerned about the non-linear progress. Other users share similar experiences, suggesting shedding is normal and cyclical, with some recommending less frequent microneedling.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The user is trying to maximize minoxidil's effectiveness by applying it for only one hour to avoid spreading it to furniture and pets, especially cats. They experience side effects when combining minoxidil with dermarolling and are considering alternatives like oral minoxidil or microneedling.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The user is considering storing Fluridil in a different container for easier application and asks if it can be mixed with Minoxidil or if hair styling products will affect its potency. They also inquire about the order and timing of applying these hair loss treatments.
The user is considering using 2 vials of Fluridil every other day instead of 1 vial daily for better scalp coverage. They are questioning if this method would be as effective.
Hair loss treatments like Dutasteride, RU58841, and Minoxidil may not work for everyone, as some individuals experience no improvement despite extensive use and research. Genetic factors can play a significant role, and standard treatments may not be effective for all.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.